Mounjaro Drug Interactions: What to Avoid

What medicines can you not take with Mounjaro is an important question for anyone starting tirzepatide treatment in the UK. Mounjaro (tirzepatide), authorised by the MHRA for type 2 diabetes and weight management, slows gastric emptying, which can alter how other oral medicines are absorbed. While it has no absolute drug contraindications beyond hypersensitivity, it interacts meaningfully with insulin, sulphonylureas, warfarin and oral contraceptives. Understanding these interactions, and discussing your full medicines list with a prescriber or pharmacist before starting treatment, is essential for safe and effective use.

What medicines can you not take with Mounjaro?

Mounjaro has no absolute drug contraindications beyond hypersensitivity, but insulin, sulphonylureas, warfarin and oral contraceptives all require careful management due to its gastric-emptying-slowing mechanism.

Mounjaro (tirzepatide) has no absolute drug contraindications listed in its UK Summary of Product Characteristics (SmPC) beyond hypersensitivity to the active substance or any excipient, but it does interact meaningfully with several medicine classes that require careful management. Mounjaro is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, authorised by the MHRA for type 2 diabetes and for chronic weight management in adults.^[2][8] Its mechanism of slowing gastric emptying is the primary driver of most clinically relevant interactions, because it can alter the rate at which other medicines are absorbed from the gut.^[1][6] This interaction risk applies chiefly to orally administered medicines; medicines given by injection, patch or other non-oral routes are generally not affected by delayed gastric emptying.

The medicines that require the most careful consideration alongside Mounjaro include:

• Insulin and insulin secretagogues (for example, sulphonylureas such as gliclazide), which carry an increased risk of hypoglycaemia

• Oral contraceptives, where absorption may be temporarily reduced during initiation and dose increases

• Warfarin, where altered absorption can affect the international normalised ratio (INR)

• Medicines with a narrow therapeutic index that depend on consistent gut absorption

Mounjaro is not recommended during pregnancy. People who could become pregnant should use effective contraception while taking Mounjaro. Because tirzepatide may reduce the absorption of oral contraceptives, a non-oral contraceptive method (such as a contraceptive patch, injection or intrauterine device) or an additional barrier method should be used for four weeks after starting Mounjaro and for four weeks after each dose increase, in line with the UK SmPC.^[1][3] Mounjaro should also be avoided if breastfeeding; discuss contraception and family planning with your prescriber before starting treatment.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where Mounjaro may be one option a prescriber considers if it is clinically appropriate. Before starting Mounjaro, a full medicines review is essential. Always share a complete and up-to-date list of all your medicines, including over-the-counter products and supplements, with your prescriber or pharmacist.

Which everyday drugs and supplements does Mounjaro affect?

Mounjaro can delay absorption of oral contraceptives, paracetamol and supplements such as iron and fat-soluble vitamins; a non-oral contraceptive method is advised for four weeks after starting or increasing the dose.

Mounjaro can affect the absorption of several commonly used everyday medicines and supplements because it slows gastric emptying, meaning the stomach takes longer to pass its contents into the small intestine where most absorption occurs. This delay does not necessarily make a medicine ineffective, but it can shift the timing and peak concentration of absorption in ways that matter for some products. This effect applies to medicines taken by mouth; non-oral medicines are not affected.

Oral contraceptives are a particularly important example. The UK SmPC for Mounjaro (section 4.5) advises that people using oral hormonal contraceptives should switch to, or add, a non-oral contraceptive method for four weeks after starting Mounjaro and for four weeks after each dose increase, because reduced or delayed absorption could theoretically lower contraceptive efficacy during those periods. Non-oral contraceptive methods, such as patches, injections or intrauterine devices, are not affected by delayed gastric emptying and may be preferable for people who need reliable contraception throughout treatment.

Paracetamol has been studied in pharmacokinetic trials with tirzepatide, as reported in the Mounjaro SmPC (section 5.2). Although the interaction is not considered clinically dangerous, peak paracetamol concentrations were reached more slowly, which is worth noting if paracetamol is being used for acute pain relief where a rapid effect is expected.

Common supplements to discuss with a pharmacist include:

• Iron tablets, which are already sensitive to timing and food interactions

• Fat-soluble vitamins (A, D, E and K), where altered gut transit may theoretically affect absorption, though this has not been formally studied with tirzepatide

• Calcium supplements, particularly relevant for people at risk of osteoporosis

The effects of Mounjaro on iron, vitamin and calcium absorption are theoretical rather than established in clinical studies; raise these with your pharmacist if you take them regularly. Herbal products such as St John's Wort are not specifically studied with Mounjaro, but because St John's Wort is a known inducer of drug-metabolising enzymes and can interact with many medicines, it should always be disclosed to a prescriber. When in doubt about any supplement, ask your pharmacist before starting it alongside Mounjaro.

How does Mounjaro interact with diabetes and heart medicines?

The most significant interactions involve insulin and sulphonylureas, which increase hypoglycaemia risk, and warfarin, which requires more frequent INR monitoring when Mounjaro is started or the dose is changed.

The most clinically significant interactions with Mounjaro involve medicines used to manage type 2 diabetes and cardiovascular conditions, and these require active monitoring rather than automatic avoidance. The risk of hypoglycaemia (low blood glucose) is the most important concern when Mounjaro is combined with other glucose-lowering agents.

Insulin: When Mounjaro is added to an existing insulin regimen, the UK SmPC (section 4.4) recommends considering a reduction in insulin dose to lower the risk of hypoglycaemia. This dose adjustment should only be made under medical supervision. Patients should be counselled on the symptoms of hypoglycaemia, which include sweating, trembling, confusion and palpitations, and should know how to treat it promptly.

Sulphonylureas (such as gliclazide, glipizide and glibenclamide): These stimulate the pancreas to release insulin regardless of blood glucose level, so combining them with Mounjaro increases hypoglycaemia risk, as noted in the UK SmPC (section 4.4). NICE guidance on type 2 diabetes management (NG28) supports reviewing sulphonylurea doses when a GLP-1-based therapy is introduced.^[9][10]

Warfarin: Warfarin has a narrow therapeutic index and its effect is measured by the INR. The UK SmPC (section 4.5) advises more frequent INR monitoring when starting Mounjaro or changing the dose, because delayed gastric emptying may alter warfarin absorption. Direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban are not specifically addressed in the Mounjaro SmPC in the same way; if you take a DOAC, inform your prescriber so they can assess whether any additional monitoring is appropriate.

Antihypertensives: Mounjaro is associated with modest reductions in blood pressure as part of its broader cardiometabolic effects, as observed in clinical trial data.^[13] Patients already taking antihypertensive medicines should have their blood pressure monitored, as dose adjustments may occasionally be needed to avoid excessive lowering.

DPP-4 inhibitors (such as sitagliptin or alogliptin): Combining a GLP-1-based therapy with a DPP-4 inhibitor is generally not recommended, as there is limited evidence of additive benefit and the combination is not supported by NICE guidance (NG28).^[10][9] Discuss with your diabetes team if you are currently taking both.

What side effects should you watch for when mixing medicines?

Hypoglycaemia is the most urgent risk when combining Mounjaro with insulin or sulphonylureas; persistent vomiting, severe abdominal pain or signs of allergic reaction also require prompt medical attention.

When Mounjaro is taken alongside other medicines, certain side effects become more likely or more serious, and knowing what to look for helps you seek the right level of care promptly. The most important signals to monitor are hypoglycaemia, gastrointestinal symptoms that may mask or mimic other conditions, and signs of rare but serious reactions.

Hypoglycaemia is the most urgent concern for people taking Mounjaro with insulin or sulphonylureas. Symptoms include shakiness, sweating, pallor, rapid heartbeat, confusion and, in severe cases, loss of consciousness. Mild hypoglycaemia can usually be treated with fast-acting glucose (for example, glucose tablets or a small glass of fruit juice), but if a person cannot swallow safely or does not recover quickly, call 999 immediately.

Gastrointestinal effects such as nausea, vomiting, diarrhoea and constipation are among the most commonly reported side effects of Mounjaro. These can affect how reliably other oral medicines are absorbed, particularly if vomiting occurs shortly after taking an oral medicine. If persistent vomiting or severe abdominal pain develops, contact your GP or call NHS 111 for advice, as these symptoms can occasionally indicate pancreatitis. The UK SmPC notes that acute pancreatitis, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome, has been reported with tirzepatide.

Diabetic retinopathy: The UK SmPC (section 4.4) advises that patients with pre-existing diabetic retinopathy should be monitored for worsening of their condition, particularly if glycaemic control improves rapidly. If you have a history of diabetic retinopathy and are starting Mounjaro, ensure your retinal monitoring appointments are up to date and report any new or worsening visual symptoms to your eye care team or GP promptly.

Allergic reactions: Although hypersensitivity is the only contraindication listed in the UK SmPC, any signs of a serious allergic reaction, including widespread rash, swelling of the face or throat, or difficulty breathing, require immediate emergency care via 999.

Suspected side effects from Mounjaro, including any that may relate to interactions with other medicines, can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

How should you talk to your GP or pharmacist about your medicines?

Bring a complete list of all prescription medicines, over-the-counter products and supplements to your prescriber or pharmacist before starting Mounjaro, and revisit monitoring plans after each dose increase.

Discussing your full medicines list with a GP or pharmacist before starting Mounjaro is the single most effective step you can take to reduce the risk of interactions. A structured medicines review allows a clinician to identify potential interactions, adjust doses where needed, and set up appropriate monitoring. This conversation should happen before your first dose, not after.

To make the most of that conversation, prepare the following information:

• A complete list of all prescription medicines, including dose and frequency

• All over-the-counter medicines you use regularly, such as ibuprofen, antacids or antihistamines

• All vitamins, minerals and herbal supplements

• Any medicines you take only occasionally, such as migraine treatments or sleep aids

• Details of any recent changes to your medicines in the past three to six months

Your pharmacist is an accessible first point of contact for medicines queries and can check for interactions using clinical databases without the need for an appointment. If you are already taking warfarin, insulin or a sulphonylurea, ask your GP or diabetes team specifically about monitoring plans and whether any dose adjustments are needed when Mounjaro is introduced. It is also important to revisit these monitoring arrangements after each dose increase, as the interaction risk with warfarin and hypoglycaemia risk with insulin or sulphonylureas may change as the tirzepatide dose is escalated.

If you experience new or unexpected symptoms after starting Mounjaro, particularly those that could reflect a change in how another medicine is working, contact your GP in the first instance. For urgent advice outside GP hours, NHS 111 is the appropriate route. Do not stop any prescribed medicine without speaking to a clinician first, as abrupt discontinuation of some medicines (for example, antihypertensives or antidiabetic agents) can itself carry risks. Regular follow-up appointments are an important part of safe long-term management on Mounjaro.

Scientific References

1. Mounjaro KwikPen 2.5 mg–15 mg solution for injection – Summary of Product Characteristics.
2. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
3. Mounjaro – EPAR product information (tirzepatide).
4. Women on 'skinny jabs' must use effective contraception, MHRA urges in latest guidance.
5. Tirzepatide – Interactions. British National Formulary.
6. Tirzepatide – Drug monograph. British National Formulary.
7. Mounjaro KwikPen 10 mg solution for injection – Summary of Product Characteristics (section 5.2).
8. Four-dose Mounjaro KwikPen approved by MHRA for diabetes and weight management.
9. Type 2 diabetes in adults: management (NG28) – Further medication chapter.
10. Type 2 diabetes in adults: management (NG28) – Visual summary: choosing medicines for first-line and further treatment.
11. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
12. Tirzepatide for treating type 2 diabetes (TA924).
13. Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.
14. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
15. Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations.
16. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

Frequently Asked Questions